Oxford Nanopore reaffirms FY rev growth of 20-23%

Oxford Nanopore reaffirms FY rev growth of 20-23%

Oxford Nanopore Technologies (ONT) has reaffirmed its forecast for full-year revenue growth, projecting a range of 20% to 23% for the fiscal year ending in June 2025 [1]. The company's latest update underscores its robust growth trajectory, driven by strong demand for its innovative sequencing technologies.

The consensus among Wall Street analysts is overwhelmingly positive, with five out of five analysts rating ONT as a "buy." The average price target for ONT stands at GBX 232.50, indicating a forecasted upside of 28.52% from the current price of GBX 180.90 [1]. Analysts from Berenberg Bank, Citigroup, and Royal Bank of Canada have contributed to this bullish outlook, highlighting ONT's potential for continued growth.

ONT's stock price has shown resilience, with analysts predicting a significant increase in share value. The consensus rating for ONT is "Buy," while the average rating for "medical" companies is "Moderate Buy," indicating that ONT is favored more than its competitors [1].

The company's latest financial projections reflect its commitment to innovation and market leadership in the sequencing technology sector. As ONT continues to expand its portfolio and enter new markets, investors can expect to see further growth in revenue and shareholder value.

References:
[1] https://www.marketbeat.com/stocks/LON/ONT/forecast/